


Business Report

As of December 31, 2025



Disclaimer

This English translation has been prepared by Lunit Inc. solely for informational and reference purposes based on the Korean version of the Business Report. The financial information included herein is based on the audited financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

In the event of any discrepancy or inconsistency between the Korean version and this English translation, the Korean version shall prevail. The Company does not undertake any obligation to update or revise this English translation to reflect events or circumstances after the date hereof.

I. CEO Message	4
II. Company History.....	5
III. Board of Directors	7
IV. Business Report	8
1. Overview of Company.....	8
2. Sales Progress and Performance.....	12
3. Status of Parent Company and Subsidiaries.....	13
4. Operation Results & Financial Condition for Past 3 Years.....	15
5. Tasks Facing the Company.....	17
6. Directors and Auditors.....	18
7. Major Shareholders	18
8. Ownership Status of Affiliates and Subsidiaries.....	18
9. Major Creditors, Etc.....	19
10. Events after the Reporting Period.....	19
11. Other Important Matters Related to Operations	19
V. Financial Statements	20
1. Consolidated Statements of Financial Position	20
2. Consolidated Statements of Comprehensive Income	21
3. Consolidated Statements of Changes in Equity.....	22
4. Consolidated Statements of Cash Flow	23
5. Separate Statements of Financial Position	24
6. Separate Statements of Comprehensive Income	25
7. Separate Statements of Changes in Equity.....	26
8. Separate Statements of Cash Flows	27

I. CEO Message

Dear Esteemed Shareholders,

Amid shifts in the medical AI industry, Lunit has focused on core competitiveness for its next leap. Even in an uncertain business environment, Lunit has moved forward steadily, backed by the trust of our shareholders.

Last year, Lunit took a meaningful step to maximize global business synergies and grow revenue in the United States (U.S.) market. Following the 2024 acquisition of Volpara, we renamed it Lunit International and advanced integration, strengthening our foundation as a global medical AI company. The differentiated U.S. data and infrastructure secured through this process will support future market leadership and profitability.

In oncology, we are also delivering notable results through deeper technology. Partnerships with global Big Pharma companies, including Daiichi-Sankyo and AstraZeneca, show that Lunit's AI technology has moved beyond the lab and is proving its real-world clinical applicability.

If 2025 was a year to regroup and prepare for takeoff, 2026 will be the year Lunit proves its potential as tangible value. We ask for your warm support on our bold journey to conquer cancer through AI.

We sincerely appreciate the continued support and encouragement of our shareholders.

Thank you.



CEO
Brandon Beomseok Suh

II. Company History

2013	<ul style="list-style-type: none"> Foundation of the company (as CLDI)
2014	<ul style="list-style-type: none"> Seed Investment by Kakao Ventures (\$0.1M)
2015	<ul style="list-style-type: none"> Pivots to medical imaging – Changes name to Lunit Series A investment led by Softbank Ventures Asia (\$2M)
2016	<ul style="list-style-type: none"> Series A1 investment led by Softbank Ventures Asia (\$3.3M) Ranked 1st place in MICCAI Tumor Proliferation Assessment Challenge 2016
2017	<ul style="list-style-type: none"> Top 100 AI Startup, by CB Insights (Only Korean company selected) Ranked 1st place in CAMELYON Grand Challenge 2017
2018	<ul style="list-style-type: none"> Series B investment led by Interset (\$15M) Ministry of Korea Food and Drug Safety (MFDS) clearance - Lunit INSIGHT CXR Nodule Established Lunit subsidiary, Lunit USA in the U.S.
2019	<ul style="list-style-type: none"> MFDS clearance - Lunit INSIGHT MMG Signed AI solution distribution and supply partnership with Fujifilm Series B1 investment led by Fujifilm (\$5M) MFDS clearance - Lunit INSIGHT CXR MCA Digital Health 150, by CB Insights (Only Korean company selected) Ranked 1st place in Visual Domain Adaptation Challenge Series C-Tranche A investment led by Shinhan Investment (\$27M)
2020	<ul style="list-style-type: none"> CE marked in Europe - Lunit INSIGHT MMG Technology Pioneer 2020, by World Economic Forum (Davos Forum, Only Korean company selected) Signed AI solution distribution and supply partnership with GE Healthcare Digital Health 150, by CB Insights (Only Korean company selected)
2021	<ul style="list-style-type: none"> Signed AI solution distribution and supply partnership with Agfa Signed AI solution distribution and supply partnership with Philips Signed AI solution joint research partnership with Guardant Health Series C-Tranche B investment by Guardant Health (\$26M) U.S. FDA clearance - Lunit INSIGHT CXR Triage, Lunit INSIGHT MMG Certified as World Class Product of Korea by Ministry of Trade, Industry, and Energy - Lunit INSIGHT The 1st Government award for Innovative Medical Devices Commendation of the Minister of Health and Welfare Pre-IPO round investment led by HealthQuest and Naver (\$61M) Digital Health 150, by CB Insights (Only Korean company selected)
2022	<ul style="list-style-type: none"> CE marked in Europe - Lunit SCOPE PD-L1 TPS Signed joint bidding agreement with Hologic Initial Public Offering - KOSDAQ Unicorn Community, by World Economic Forum (Davos Forum) Selected as the preferred AI technology for Australian National Breast Screen New South Wales (BSNSW)

2023

- Launched in Europe - **Lunit INSIGHT DBT**
- Established Lunit subsidiary, Lunit Europe Holdings in Europe
- 2023 Science, Information and Communication Day - **Science and Technology Promotion Division Presidential Commendation**
- CXR-AID officially included as an eligible solution for health insurance reimbursement in Japan
- U.S. FDA clearance - **Lunit INSIGHT DBT**
- **Lunit INSIGHT CXR** - Authorized as Innovative Medical Technology
- **Associate Partner**, by World Economic Forum (Davos Forum)

2024

- **Lunit INSIGHT MMG** - Designated as a New Health Technology (evaluation deferred)
- Acquired 100% stake in **Volpara Health Technologies Ltd.** based in New Zealand
- Volpara signs a breast cancer screening software supply agreement with Intermountain Health in the U.S.
- Joint development of AI-powered pathology solutions with AstraZeneca
- Volpara signs a supply contract with the U.S. Defense Health Agency (DHA) for breast cancer screening software


2025

- MFDS Clearance - **Lunit INSIGHT DBT**
- Volpara signs a supply contract with SimonMed Imaging for breast cancer screening software
- CE marked in Europe - **Lunit INSIGHT CXR4**
- Acquired key technology assets from U.S.-based Prognosis
- U.S. FDA Clearance Submitted - **Lunit INSIGHT Risk**
- Renamed Volpara Health Technologies Ltd. and Volpara Health Inc. to Lunit International Ltd. and Lunit Americas Inc.

III. Board of Directors

To respond swiftly to the rapidly evolving medical AI industry and fast-changing global business environment, Lunit has established a Board composed of leading experts in biotechnology, AI, finance and accounting, Capital Market, law and policy. The Board consists of six directors: two inside directors, two independent directors and two non-executive directors, and Lunit pursues diversity in Board composition regardless of age, gender or nationality. As its highest decision-making body, the Board reviews and approves key corporate matters. In 2025, Lunit held 6 Board meetings and conducted in-depth discussions on 28 items, including 15 resolutions and 13 reporting/discussion items.

Lunit operates the Audit Committee and Compensation Committee under the Board to strengthen Board expertise and decision-making independence. Lunit’s Audit Committee serves as a key oversight body that supervises management in compliance with applicable laws and regulations while enhancing accounting and financial transparency. In addition, Lunit operates the Compensation Committee to maximize objectivity and transparency in determining executive and director compensation.



IV. Business Report

1. Overview of Company

A. Objectives of the Company

1. Development of technologies and services utilizing visual data (images/videos)
2. Development, manufacture, distribution, advisory, maintenance and services of image-based product search solutions
3. Development, manufacture, distribution, advisory and maintenance of software
4. Data processing and database business
5. Manufacture, sale, import, lease and repair of medical devices
6. Other professional, scientific and technical service businesses
7. Medical and pharmaceutical research and development business
8. Information service business (information processing and provision technologies)
9. Mobile business
10. Content development business
11. Sale of hardware and peripheral devices
12. Technology services business
13. Other insurance and pension related services
14. E-commerce related services and distribution
15. Real estate development, supply and leasing business
16. Food and beverage sales and cafe operation
17. Any e-commerce and mail-order sales related to the above businesses
18. Wholesale, retail, import/export, and agency services related to the above businesses
19. Any and all incidental businesses related to the above

B. Details of Major Businesses

- The Company has developed and commercialized deep learning-based AI solutions that overcome the limitations of human vision in medical image interpretation, thereby strengthening its competitiveness in the medical AI market. The Company is also developing AI imaging biomarker solutions that analyze pathology images to identify novel imaging biomarkers beyond the limits of human visual cognition and pattern recognition and expand the application of AI in healthcare.
- The Company's principal products and services include Lunit INSIGHT, an AI-powered medical image interpretation solution, and breast cancer screening software in the Cancer Screening segment, and Lunit SCOPE, an AI imaging biomarker solution for the Oncology segment. Based on their functions, the product portfolio is categorized as follows. In the Cancer Screening segment, the Company offers: (1) solutions that assist medical image interpretation for early cancer detection; (2) solutions that identify imaging biomarkers based on medical images to predict cancer risk; and (3) solutions that provide breast density analysis and breast cancer risk assessment based on mammography images. In the Oncology segment, the Company offers: (1) solutions that assist in pathology slide interpretation to quantify biomarker expression levels; and (2) solutions that identify novel imaging biomarkers to predict treatment responses to immuno-oncology therapies and other treatments.
- The Company has established global sales and R&D networks across major international markets. For the year ended December 31, 2025, on consolidated basis, the Company recorded revenue of

KRW 83,129 million, of which 92% was generated overseas. For Lunit INSIGHT, the Company has expanded its global sales network through partnerships with leading medical imaging companies, including GE Healthcare, Philips, Fujifilm, and Hologic, while also strengthening direct sales operations through subsidiaries in key markets such as the U.S. and Japan. In May 2024, the Company completed the acquisition of New Zealand-based Lunit International Ltd. (formerly Volpara Health Technologies, Ltd.), establishing a strong foundation for expansion into the U.S. market. Lunit International Ltd. provides breast cancer-related software for cancer risk assessment and breast density analysis and has an extensive global network used by more than 9,500 healthcare professionals across over 3,600 institutions worldwide. For Lunit SCOPE, the Company is expanding its research-use-only (RUO) business with pharmaceutical companies, clinical research organizations, diagnostic testing service providers, and Guardant Health, a global leader in liquid biopsy. Through these RUO collaborations, the Company aims to generate clinical evidence and strengthen its market presence, with the long-term goal of obtaining companion diagnostics (CDx) approvals to expand into the clinical market.

C. Headquarters and Branch Offices

Category	Country	Company Name	Main Business
Headquarters	Republic of Korea	Lunit Inc.	Development and supply of medical AI software
Subsidiary	United States	Lunit USA, Inc.	
	China	Lunit China Co., Ltd.	
	Netherlands	Lunit Europe Holdings B.V.	
	Japan	Lunit Japan Inc.	
	New Zealand	Lunit International Ltd.	
Sub-subsidiary	Germany	Lunit Europe GmbH ¹⁾	
	New Zealand	Lunit Finance NZ Ltd. ²⁾	
	New Zealand	Volpara Health Ltd. ²⁾	
	Canada	Lunit Canada, Inc. ²⁾	
	Denmark	Lunit Denmark ApS ²⁾	
	United States	Lunit Americas, Inc. ²⁾	
	Australia	Lunit Australia Pty Ltd. ²⁾	
United Kingdom	Lunit UK Ltd. ²⁾		

1) A wholly owned subsidiary of Lunit Europe Holdings B.V.

2) A wholly owned subsidiary of Lunit International Ltd.

D. Employees


(Unit: persons)

R&D	Sales & Marketing	Admin	Total
272	150	95	517

1) Based on consolidated headcount, including subsidiaries.

2) Excluding registered executives and outside directors.

E. Organization Chart



1) Based on the headquarters only.

F. Stock Information

1. Class and number of issued shares

(Unit: shares, KRW thousand, %)

Class	No. of Shares	Amount	Composition	Notes
Common Stock	29,256,746	14,628,373	100.00	-
Total	29,256,746	14,628,373	100.00	-

2. Changes in Capital Stock

(Unit: shares, KRW thousand)

Date (yyyy.mm.dd.)	Class of Shares	No. of Shares	Amount of Capital Increase (Reduction)	Capital Stock After Increase (Reduction)	Capital Increase (Reduction) Description
2021.02.08.	Common Stock	1,328	664	840,464	Exercise of Stock Options
2021.03.25.	Common Stock	10,066	5,033	845,497	Exercise of Stock Options
2021.04.10.	Common Stock Preferred Stock	6,763,972	3,381,986	4,227,483	Bonus Issue ²⁾ (4 shares issued for each existing share)
2021.07.08.	Preferred Stock	775,000	387,500	4,614,983	Capital Increase ²⁾
2021.07.21.	Common Stock	32,835	16,418	4,631,400	Exercise of Stock Options
2021.11.23.	Common Stock	7,940	3,970	5,413,862	Exercise of Stock Options
	Preferred Stock	1,556,983	778,492		Capital Increase ²⁾
2021.11.24.	Preferred Stock	80,743	40,372	5,454,233	Capital Increase ²⁾
2022.07.16.	Common Stock	1,215,800	607,900	6,078,800	Capital Increase (Public Offering, IPO)
	Common Stock	33,333	16,667		Capital Increase (Third-Party Allotment to Underwriter)
2022.08.16.	Common Stock	65,879	32,940	6,111,739	Exercise of Stock Options
2022.10.17.	Common Stock	4,150	2,075	6,113,814	Exercise of Stock Options

2023.01.13.	Common Stock	27,557	13,779	6,127,593	Exercise of Stock Options
2023.04.14.	Common Stock	85,469	42,735	6,170,327	Exercise of Stock Options
2023.07.14.	Common Stock	40,350	20,175	6,190,502	Exercise of Stock Options
2023.11.10.	Common Stock	1,857,150	928,575	7,119,077	Capital Increase
2023.11.10.	Common Stock	14,238,154	7,119,077	14,238,154	Bonus Issue (1 share issued for each existing share)
2023.12.21.	Common Stock	225,969	112,985	14,351,139	Exercise of Stock Options
2024.01.19.	Common Stock	57,533	28,767	14,379,905	Exercise of Stock Options
2024.04.19.	Common Stock	70,820	35,410	14,415,315	Exercise of Stock Options
2024.07.16.	Common Stock	42,522	21,261	14,436,576	Exercise of Stock Options
2024.10.18.	Common Stock	69,748	34,874	14,471,450	Exercise of Stock Options
2025.01.21.	Common Stock	52,340	26,170	14,497,620	Exercise of Stock Options
2025.04.22.	Common Stock	154,678	77,339	14,574,959	Exercise of Stock Options
2025.07.21.	Common Stock	54,672	27,336	14,602,295	Exercise of Stock Options
2025.10.20.	Common Stock	52,156	26,078	14,628,373	Exercise of Stock Options

1) Represents changes in capital stock over the past five years.

2) Converted into common stock upon the exercise of conversion rights.

3. Stock Affairs

Fiscal Year-End	December 31		
Record Date	Last day of each fiscal year	Annual General Meeting of Shareholders	Within 3 months after the end of each fiscal year
Public Notice Method	Company website (www.lunit.io) or The Korea Economic Daily		
Type of Share Certificate	_1)		
Transfer Agent	Korea Securities Depository (T. +82-51-519-1500)		

1) Pursuant to the “Act on Electronic Registration of Stocks, Bonds, etc.,” the rights required to be indicated on share certificates and share warrant certificates were mandatorily registered electronically on January 4, 2022. Accordingly, the “Type of Share Certificate” is not stated.

4. Bonds Information

- The Company issued two rounds of privately placed unsecured convertible bonds in May 2024. The first tranche was issued on May 3, 2024, and the second tranche was issued on May 31, 2024. For further details, please refer to the “Results of Securities Issuance (Voluntary Disclosure)” disclosures dated May 3, 2024 and May 31, 2024.

2. Sales Progress and Performance

A. Overview of Sales

1. Cancer Screening (AI-Assisted Medical Imaging Analysis)

- Lunit INSIGHT CXR and Lunit INSIGHT MMG are AI-assisted imaging analysis solutions for the Cancer Screening segment. Lunit INSIGHT CXR detects more than 10 types of abnormalities in chest X-ray images, while Lunit INSIGHT MMG detects suspicious breast cancer lesions and classifies breast density in mammography images. Lunit INSIGHT CXR received regulatory approval from the Korean Ministry of Food and Drug Safety (MFDS) in August 2018, while Lunit INSIGHT CXR Triage, designed to identify urgent conditions such as pneumothorax and pleural effusion, received U.S. Food and Drug Administration (FDA) clearance in November 2021. In addition, in November 2022, both Lunit INSIGHT CXR and Lunit INSIGHT MMG obtained CE certification under the EU Medical Device Regulation (MDR), enabling the Company to proactively respond to evolving regulatory requirements in the European market. The Company also launched Lunit INSIGHT DBT, which assists physicians by detecting suspicious breast cancer lesions in digital breast tomosynthesis images. Lunit INSIGHT DBT obtained CE certification in Europe in February 2023, U.S. FDA clearance in November 2023, and Korean MFDS approval in April 2025, supporting the Company's global market expansion.
- The business model of Lunit INSIGHT consists of: (1) integration with Picture Archiving and Communication Systems (PACS) ("Platform model"); (2) integration with or embedding into medical imaging equipment ("Modality model"); and (3) subscription-based Software-as-a-Service ("SaaS") offerings. Under the Platform model, the Company charges a fixed fee per image analyzed and bills customers through monthly or quarterly subscriptions. Under the Modality model, the Company charges a fixed fee per imaging device sold and additionally collects annual maintenance fees. Under the SaaS model, customers enter into long-term usage agreements and prepay annual subscription fees.
- To support these business models, the Company collaborates with global manufacturers in the X-ray imaging equipment, mammography equipment, and PACS markets, enabling bundled offerings and joint sales activities. The Company has entered into distribution and sales agreements with global medical device companies such as GE Healthcare, Philips, Fujifilm, and Hologic, as well as healthcare IT companies including Agfa, Sectra, and Emergent Connect. As these partners collectively account for nearly 50% of their respective markets, the Company expects to further accelerate market penetration and business expansion. As of the end of 2025, more than 7,400 medical institutions worldwide had adopted Lunit INSIGHT.
- In addition, leveraging the U.S. sales channels and other networks of Lunit International Ltd., which the Company acquired in May 2024, the Company is expanding its direct sales operations in addition to partner-based sales. Lunit International Ltd. has established direct sales channels in key markets including the U.S., Canada, Australia, and New Zealand, allowing the Company to build closer relationships with customers.

2. Oncology (Cancer Treatment Response Prediction)

- Lunit SCOPE, the Company's AI imaging biomarker solution for the Oncology segment, is currently used to predict responses to immuno-oncology therapies by quantifying the expression levels of biomarkers such as PD-L1 and TIL. The Company has completed research and development for solutions capable of predicting treatment responses to immuno-oncology therapies across lung cancer and 15 additional cancer types and generated its first RUO revenue in the third quarter of 2023. The Company is currently entering into research agreements with multiple global pharmaceutical companies and aims to obtain clinical approval for use as a companion diagnostic

(CDx) biomarker for cancer therapies.

- Lunit SCOPE has also conducted collaborative research with leading hospitals and research institutions in Korea and has demonstrated its technological capabilities through various clinical publications. In June 2021, the Company entered into a partnership with Guardant Health, a global leader in liquid biopsy, enabling the Company to leverage an extensive clinical network for developing and validating novel biomarkers for use in real-world clinical settings.
- Through its collaboration with Guardant Health, the Company recognized milestone revenue from research and development activities in 2023 and successfully completed the joint development and launch of collaborative products. In addition, the Company continues to expand its research beyond immuno-oncology therapies into targeted therapies and antibody-drug conjugates (ADCs).

B. Sales Performance

(Unit: KRW million)

Category		2025 (13 th)		2024 (12 th)		2023 (11 th)	
		Amount	%	Amount	%	Amount	%
Cancer Screening	Software	67,465	81.16	46,212	85.29	18,019	71.85
	Others	5,290	6.36	3,962	7.31	329	1.31
Oncology	Services	10,101	12.15	3,429	6.33	6,115	24.38
	Others	273	0.33	576	1.06	583	2.32
Others		-	-	1	0.01	34	0.14
Total		83,129	100.00	54,180	100.00	25,080	100.00

(Unit: KRW million)

Category	2025 (13 th)	2024 (12 th)
Domestic Sales	6,330	6,417
Overseas Sales	76,799	47,763
Total	83,129	54,180

(Unit: KRW million)

Category	2025 (13 th)	2024 (12 th)
Company A ¹⁾	10,514	11,155
Total	10,514	11,155

1) Represents more than 10% of consolidated revenue.

3. Status of Parent Company and Subsidiaries

A. Parent Company

- None

B. Subsidiaries

(Unit: shares, %)

Company Name	Subsidiaries		Relation with Company		
	Capital	Main Business	No. of Shares	Ownership (%)	Transaction Relationship
Lunit USA, Inc.	USD 33,600	Development and supply of medical AI software	336,000	100.00	-
Lunit China Co., Ltd.	CNY 1,499,916		-	100.00	-
Lunit Europe Holdings B.V.	EUR 1,360,000		1,360,000	100.00	-
Lunit Japan Inc.	JPY 10,000,000		1,000	100.00	-
Lunit International Ltd.	NZD 191,659,653		260,956,512	100.00	-
Lunit Europe GmbH ¹⁾	EUR 1,060,000		1,060,000	100.00	-
Lunit Finance NZ Ltd. ²⁾	NZD 357,000		1,000	100.00	-
Volpara Health Ltd. ²⁾	NZD 1		100	100.00	-
Lunit Canada, Inc. ²⁾	CAD 100,000		1,000	100.00	-
Lunit Denmark ApS ²⁾	DKK 20,000		20,000	100.00	-
Lunit Americas, Inc. ²⁾	USD 28,910,153		10,000,000	100.00	-
Lunit Australia Pty Ltd. ²⁾	AUD 10,000		1,000,000	100.00	-
Lunit UK Ltd. ²⁾	EUR 100		10,000	100.00	-

1) A wholly owned subsidiary of Lunit Europe Holdings B.V.

2) A wholly owned subsidiary of Lunit International Ltd.

C. Executives' Concurrent Positions in Subsidiaries

Executive		Concurrent Position (Subsidiaries)	
Name	Position	Company Name	Position
Beomseok Suh	CEO (Registered Executive)	Lunit USA, Inc.	CEO (Registered Executive)
		Lunit China Co., Ltd	CEO (Registered Executive)
		Lunit Europe Holdings B.V.	CEO (Registered Executive)
		Lunit Japan Inc.	CEO (Registered Executive)
		Lunit International Ltd.	Director
		Lunit Finance NZ Ltd.	Director
		Volpara Health Ltd.	Director
		Lunit Americas, Inc.	Director

Seungwook Paek	Inside Director (Registered Executive)	Lunit USA, Inc.	Director
		Lunit International Ltd.	Director
		Lunit Finance NZ Ltd.	Director
		Volpara Health Ltd.	Director
		Lunit Americas, Inc.	Director
Hyeonseong Park	Inside Director (Non-registered Executive)	Lunit USA, Inc.	Executive Officer

4. Operation Results & Financial Condition for Past 3 Years

A. Summary Consolidated Statements of Financial Position: 2023–2025

- The summary consolidated statements of financial position for the 13th, 12th, and 11th fiscal years are externally audited summary consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

(Unit: KRW)

Account	2025 (13 th)	2024 (12 th)	2023 (11 th)
1. Current assets	55,619,662,929	111,882,055,343	230,417,590,193
2. Non-current assets	314,292,034,266	321,032,423,264	37,503,109,970
Total assets	369,911,697,195	432,914,478,607	267,920,700,163
1. Current liabilities	212,212,100,968	252,412,814,540	12,793,897,901
2. Non-current liabilities	20,266,695,958	17,766,852,239	20,017,295,478
Total liabilities	232,478,796,926	270,179,666,779	32,811,193,379
[Equity attributable to owners of parent]			
1. Issued capital	14,628,373,000	14,471,450,000	14,351,138,500
2. Capital surplus	549,031,241,883	526,645,689,887	515,517,787,871
3. Accumulated other comprehensive income	(121,277,833)	(278,027,018)	181,438,987
4. Retained earnings (deficit)	(426,105,436,781)	(378,104,301,041)	(294,940,858,574)
[Non-controlling interests]	-	-	-
Total equity	137,432,900,269	162,734,811,828	235,109,506,784

B. Summary Separate Statements of Financial Position: 2023–2025

- The summary separate statements of financial position for the 13th, 12th, and 11th fiscal years are externally audited summary separate financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

(Unit: KRW)

Account	2025 (13 th)	2024 (12 th)	2023 (11 th)
1. Current assets	30,025,069,346	85,735,835,728	225,384,854,943
2. Non-current assets	331,028,640,842	329,030,967,997	46,477,621,257
Total assets	361,053,710,188	414,766,803,725	271,862,476,200
1. Current liabilities	185,684,151,729	222,982,138,567	13,571,617,748
2. Non-current liabilities	18,637,784,073	16,773,855,188	20,017,295,478

Account	2025 (13 th)	2024 (12 th)	2023 (11 th)
Total liabilities	204,321,935,802	239,755,993,755	33,588,913,226
1. Issued capital	14,628,373,000	14,471,450,000	14,351,138,500
2. Capital surplus	549,031,241,883	526,645,689,887	515,517,787,871
3. Retained earnings (deficit)	(406,927,840,497)	(366,106,329,917)	(291,595,363,397)
Total equity	156,731,774,386	175,010,809,970	238,273,562,974

C. Summary Consolidated Statements of Profit or Loss: 2023–2025

- The summary consolidated statements of profit or loss for the 13th, 12th, and 11th fiscal years are externally audited summary consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

(Unit: KRW)

Account	2025 (13 th)	2024 (12 th)	2023 (11 th)
Revenue	83,129,295,404	54,179,663,335	25,080,238,712
Operating income(loss)	(83,103,910,311)	(67,947,200,428)	(42,216,718,386)
Profit (loss)	(47,389,679,756)	(82,695,495,892)	(36,798,251,578)
Other comprehensive income	(454,706,799)	(927,412,580)	99,575,946
Comprehensive income(loss)	(47,844,386,555)	(83,622,908,472)	(36,698,675,632)
Basic earnings (loss) per share	(1,627)	(2,867)	(1,420)
Diluted earnings (loss) per share	(2,825)	(2,867)	(1,420)

D. Summary Separate Statements of Profit or Loss: 2023–2025

- The summary separate statements of profit or loss for the 13th, 12th, and 11th fiscal years are externally audited summary separate financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS).

(Unit: KRW)

Account	2025 (13 th)	2024 (12 th)	2023 (11 th)
Revenue	32,822,258,104	25,718,636,502	25,080,238,712
Operating income(loss)	(76,556,335,514)	(58,981,984,803)	(40,794,581,924)
Profit (loss)	(40,210,054,596)	(74,043,019,945)	(35,322,335,019)
Other comprehensive income	(611,455,984)	(467,946,575)	59,796,415
Comprehensive income(loss)	(40,821,510,580)	(74,510,966,520)	(35,262,538,604)
Basic earnings (loss) per share	(1,380)	(2,567)	(1,363)
Diluted earnings (loss) per share	(2,604)	(2,567)	(1,363)

5. Tasks Facing the Company

A. Cash Flow Management

- The Company recorded consolidated revenue of KRW 83.1 billion in 2025, while operating loss amounted to KRW 83.1 billion.
- As the Company's operating cash flow is not yet sufficient to cover operating expenses, the Company has relied on external financing to fund a substantial portion of its operating activities. In December 2023, the Company completed a shareholder rights offering, and in May 2024, the Company issued privately placed convertible bonds to secure operating funds and financing for equity investments.
- Following the 2025 fiscal year-end, the Company is proceeding with a shareholder rights offering to secure funds for debt repayment and operations, and therefore remains focused on prudent cash flow management.
- The Company is managing operating expenses to support continued business expansion until revenue becomes more stable. In particular, as uncertainties in the macroeconomic environment are expected to persist, management of cash expenditures and cash balances has become increasingly important.

B. Business Model Diversification

- The AI-based software developed by the Company represents a new category of AI-based medical software. As a result, the Company is able to pursue a variety of business models, and establishing appropriate business models is considered a key factor for mid- to long-term growth.
- For Lunit INSIGHT, the Company has established business models based on PACS integration ("Platform model") and device integration ("Modality model"), while also pursuing additional business opportunities such as B2C services, collaborations with insurance companies, and AI-generated reports. In addition, the Company is expanding into AI-based cancer risk prediction using medical imaging and is diversifying its business models by expanding the applicability of medical AI solutions through the development of foundation models utilizing various medical datasets.
- For Lunit SCOPE, the Company is developing business models through collaborations with global pharmaceutical companies, participation in clinical trials, and partnerships with insurance companies. In the mid to long term, the Company aims to expand the clinical application of Lunit SCOPE through regulatory approvals.

6. Directors and Auditors

Classification	Name	Position	Responsibilities	Relationship with the Company
Full-time / Registered	Beomseok Suh	CEO (Inside Director)	Chief Executive Officer	-
	Seungwook Paek	Inside Director	Executive Chairman	Largest Shareholder
Non-full-time / Registered	Garheng Kong	Non-executive Director	Management Advisory Compensation Committee Member	-
	Wonbok Lee	Independent Director	Management Advisory Audit Committee Member	-
	Zeongwon Kim	Independent Director	Management Advisory Audit Committee Member Compensation Committee Member	-
	Joonpyo Lee	Non-executive Director	Management Advisory Audit Committee Member	-
Full-time / Unregistered	Jungin Lee	Director	Dept. Head of Infrastructure	-
	Donggeun Yoo	Director	Chief AI Officer	-
	Sunggyun Park	Director	Chief Operating and Regulation Officer	-
	Kyunghyun Paeng	Director	Chief Product Officer	-
	Kihwan Kim	Director	Head of Cancer Screening Group	-
	Hyeonseong Park	Director	Chief Financial Officer	-
	Ken Nesmith	Director	Head of Oncology Group	-
	Richard Yoo	Director	Chief Technology Officer	-

7. Major Shareholders

(Unit: shares, %)

Name of shareholder	No. of Shares	Ownership (%)	Transaction Relationship with the Company	Notes
Seungwook Paek	1,976,864	6.76	Largest Shareholder	-

8. Ownership Status of Affiliates and Subsidiaries

(Unit: shares, %)

Investee	Investor	Investor's investments to Investee		Investee's investments to the Company	
		No. of shares owned	Ownership (%)	No. of shares owned	Ownership (%)
Lunit USA, Inc.	Lunit Inc.	336,000	100.00	-	-
Lunit China Co., Ltd.	Lunit Inc.	-	100.00	-	-
Lunit Europe Holdings B.V.	Lunit Inc.	1,360,000	100.00	-	-
Lunit Japan Inc.	Lunit Inc.	1,000	100.00	-	-
Lunit International Ltd.	Lunit Inc.	260,956,512	100.00	-	-
Lunit Europe GmbH	Lunit Europe Holdings B.V.	1,060,000	100.00	-	-
Lunit Finance NZ Ltd.	Lunit International Ltd.	1,000	100.00	-	-

Volpara Health Ltd.	Lunit International Ltd.	100	100.00	-	-
Lunit Canada, Inc.	Lunit International Ltd.	1,000	100.00	-	-
Lunit Denmark ApS	Lunit International Ltd.	20,000	100.00	-	-
Lunit Americas, Inc.	Lunit International Ltd.	10,000,000	100.00	-	-
Lunit Australia Pty Ltd.	Lunit International Ltd.	1,000,000	100.00	-	-
Lunit UK Ltd.	Lunit International Ltd.	10,000	100.00	-	-

9. Major Creditors, Etc.

- The Company's major creditors include the underwriting institutions of the 1st and 2nd convertible bonds issued by the Company in May 2024. For further details, please refer to the "Report on Securities Issuance Results (Voluntary Disclosure) (1st CB)" and "Report on Securities Issuance Results (Voluntary Disclosure) (2nd CB)" disclosed on May 3, 2024 and May 31, 2024, respectively.

10. Events after the Reporting Period

1. Paid-in Capital Increase and Bonus Issue

- At the Board of Directors meetings held on January 30, 2026 and February 27, 2026, the Company resolved to conduct a paid-in capital increase through the issuance of 7,906,816 new common shares, as well as a bonus issue allocating one new share for each existing share held. For further details, please refer to the "[Final Terms Determined] Securities Registration Statement (Equity Securities)" and the "Prospectus" disclosed on March 17, 2026.

11. Other Important Matters Related to Operations

- None

V. Financial Statements

1. Consolidated Statements of Financial Position

	(Unit: KRW)	
	2025 (13 th)	2024 (12 th)
Assets		
Current assets	55,619,662,929	111,882,055,343
Cash and cash equivalents	14,110,597,196	52,369,332,882
Current trade receivables	21,802,146,800	19,121,180,786
Other current financial assets	802,588,311	5,532,590,778
Current financial assets at fair value through profit or loss	6,500,467,936	8,955,660,067
Current derivative financial assets	2,254,733,267	17,261,346,357
Current contract assets	4,566,674,908	2,620,492,737
Other current assets	4,639,050,904	4,825,501,208
Current inventories	124,283,943	115,671,778
Current tax assets	819,119,664	1,080,278,750
Non-current assets	314,292,034,266	321,032,423,264
Non-current trade receivables	5,714,030,829	4,087,156,096
Property, plant and equipment	6,238,124,127	7,846,061,381
Right-of-use assets	15,361,698,758	17,273,723,997
Intangible assets and goodwill	278,704,461,701	274,582,644,231
Non-current financial assets at fair value through profit or loss	1,380,092,823	9,778,758,110
Other non-current financial assets	1,735,411,699	1,665,747,796
Other non-current assets	4,857,271,561	4,749,205,791
Non-current net defined benefit asset	0	356,026,971
Deferred tax assets	300,942,768	693,098,891
Total assets	369,911,697,195	432,914,478,607
Liabilities		
Current liabilities	212,212,100,968	252,412,814,540
Current trade payables	6,183,388	1,069,471,245
Current loans received and current portion of non-current loans received	18,910,194,575	0
Other current financial liabilities	11,632,874,259	9,402,031,389
Current derivative financial liabilities	72,325,644,459	154,792,594,067
Current portion of convertible bonds	74,459,326,891	52,842,022,216
Current financial liabilities at fair value through profit or loss	0	1,845,458,333
Other current liabilities	34,872,157,814	32,436,729,064
Current tax liabilities	5,719,582	24,508,226
Non-current liabilities	20,266,695,958	17,766,852,239
Non-current net defined benefit liability	3,317,030,285	0
Long-term employee benefit liabilities	505,918,631	599,476,490
Non-current financial liabilities at fair value through profit or loss	0	0
Other non-current financial liabilities	14,708,730,151	16,602,917,599
Other non-current liabilities	1,117,898,994	12,250,158
Other non-current provisions	568,327,916	552,207,992
Deferred tax liabilities	48,789,981	0
Total liabilities	232,478,796,926	270,179,666,779
Equity		
Equity attributable to owners of parent	137,432,900,269	162,734,811,828
Issued capital	14,628,373,000	14,471,450,000
Capital surplus	549,031,241,883	526,645,689,887
Accumulated other comprehensive income	-121,277,833	-278,027,018
Retained earnings (deficit)	-426,105,436,781	-378,104,301,041
Non-controlling interests	0	0
Total equity	137,432,900,269	162,734,811,828
Total equity and liabilities	369,911,697,195	432,914,478,607

2. Consolidated Statements of Comprehensive Income

(Unit: KRW)

	2025 (13 th)	2024 (12 th)
Revenue	83,129,295,404	54,179,663,335
Operating expense	166,233,205,715	122,126,863,763
Operating income(loss)	-83,103,910,311	-67,947,200,428
Finance income	89,253,606,344	19,201,510,353
Finance costs	53,050,240,074	34,742,619,139
Other gains	151,025,492	107,284,279
Other losses	85,049,840	120,593,483
Profit (loss) before tax	-46,834,568,389	-83,501,618,418
Tax expense (income)	555,111,367	-806,122,526
Profit (loss)	-47,389,679,756	-82,695,495,892
Other comprehensive income	-454,706,799	-927,412,580
Other comprehensive income that will be reclassified to profit or loss, net of tax	156,749,185	-459,466,005
Gains (losses) on exchange differences on translation of foreign operations, net of tax	156,749,185	-459,466,005
Other comprehensive income that will not be reclassified to profit or loss, net of tax	-611,455,984	-467,946,575
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-611,455,984	-467,946,575
Comprehensive income	-47,844,386,555	-83,622,908,472
Profit (loss), attributable to		
Profit (loss), attributable to owners of parent	-47,389,679,756	-82,695,495,892
Profit (loss), attributable to non-controlling interests	0	0
Comprehensive income attributable to		
Comprehensive income, attributable to owners of parent	-47,844,386,555	-83,622,908,472
Comprehensive income, attributable to non-controlling interests	0	0
Earnings per share		
Basic earnings (loss) per share	-1,627	-2,867
Diluted earnings (loss) per share	-2,825	-2,867

3. Consolidated Statements of Changes in Equity

(Unit: KRW)

	Equity attributable to owners of parent				
	Issued capital	Elements of other stockholders equity	Other Comprehensive income/loss accumulated amount	Retained earnings	
2024 (12th)					
Statement of changes in equity					
Equity at beginning of period	14,351,138,500	515,517,787,871	181,438,987	-294,940,858,574	235,109,506,784
Increase (decrease) through transactions with owners, equity	120,311,500	11,127,902,016	0	0	11,248,213,516
Issue of equity	0	0	0	0	0
Increase (decrease) through exercise of warrants, equity	120,311,500	1,346,214,190	0	0	1,466,525,690
Bonus issue	0	0	0	0	0
Increase (decrease) through share-based payment transactions, equity	0	9,781,687,826	0	0	9,781,687,826
Comprehensive income	0	0	-459,466,005	-83,163,442,467	-83,622,908,472
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	0	0	0	-467,946,575	-467,946,575
Gains (losses) on exchange differences on translation of foreign operations, net of tax	0	0	-459,466,005	0	-459,466,005
Profit (loss)	0	0	0	-82,695,495,892	-82,695,495,892
Equity at end of period	14,471,450,000	526,645,689,887	-278,027,018	-378,104,301,041	162,734,811,828
2025 (13th)					
Statement of changes in equity					
Equity at beginning of period	14,471,450,000	526,645,689,887	-278,027,018	-378,104,301,041	162,734,811,828
Increase (decrease) through transactions with owners, equity	156,923,000	22,385,551,996	0	0	22,542,474,996
Issue of equity	0	0	0	0	0
Increase (decrease) through exercise of warrants, equity	156,923,000	3,106,940,780	0	0	3,263,863,780
Bonus issue	0	0	0	0	0
Increase (decrease) through share-based payment transactions, equity	0	19,278,611,216	0	0	19,278,611,216
Comprehensive income	0	0	156,749,185	-48,001,135,740	-47,844,386,555
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	0	0	0	-611,455,984	-611,455,984
Gains (losses) on exchange differences on translation of foreign operations, net of tax	0	0	156,749,185	0	156,749,185
Profit (loss)	0	0	0	-47,389,679,756	-47,389,679,756
Equity at end of period	14,628,373,000	549,031,241,883	-121,277,833	-426,105,436,781	137,432,900,269

4. Consolidated Statements of Cash Flow

(Unit: KRW)

	2025 (13 th)	2024 (12 th)
Cash flows from (used in) operating activities	-55,175,238,016	-65,696,290,063
Cash flows from (used in) operations	-52,258,509,575	-68,230,037,340
Interest received, classified as operating activities	772,521,167	4,479,446,426
Interest paid, classified as operating activities	-4,067,362,986	-1,664,273,485
Income taxes paid (refund), classified as operating activities	378,113,378	-281,425,664
Cash flows from (used in) investing activities	-2,416,519,586	-86,423,778,187
Inflows of cash from investing activities	16,724,647,576	202,923,094,420
Proceeds from sales of short term Financial Instruments	5,000,000,000	197,688,927,025
Proceeds from sales of property, plant and equipment	53,163,086	55,438,893
Proceeds from sales of long-term financial instruments	0	50,000,000
Decrease in other guarantee deposit	95,441,812	0
Proceeds from sales of fair value financial asset	11,576,042,678	5,123,128,502
Proceeds from government grants	0	5,600,000
Decrease in loans	0	0
Decrease in guarantee deposits	0	0
Outflows of cash from investing activities	-19,141,167,162	-289,346,872,607
Purchase of property, plant and equipment	-638,569,749	-5,278,116,606
Purchase of intangible assets	-8,994,819,706	-1,395,775,833
Cash advances and loans made to other parties, classified as investing activities	-814,077,740	-648,396,392
Increase in leasehold deposits	-10,282,825	-12,857,488
Increase in other guarantee deposit	-60,000,000	-178,302,318
Purchase of fair value financial asset	-8,423,417,142	-14,397,306,032
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities	0	-255,087,297,938
Purchase of short term Financial Instruments	-200,000,000	-12,348,820,000
Cash flows from (used in) financing activities	19,792,901,121	171,258,833,018
Inflows of cash from financing activities	34,142,875,917	172,966,525,690
Proceeds from exercise of share options	3,263,863,780	1,466,525,690
Proceeds from convertible bonds	0	171,500,000,000
Proceeds from short term borrowings	30,879,012,137	0
Issue of equity	0	0
Outflows of cash from financing activities	-14,349,974,796	-1,707,692,672
Payments of finance lease liabilities, classified as financing activities	-2,349,974,796	-1,707,692,672
Repayments of short term borrowings	-12,000,000,000	0
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-37,798,856,481	19,138,764,768
Cash and cash equivalents at beginning of period	52,369,332,882	31,654,786,154
Effect of exchange rate changes on cash and cash equivalents	-459,879,205	1,575,781,960
Cash and cash equivalents at end of period	14,110,597,196	52,369,332,882

5. Separate Statements of Financial Position

	(Unit: KRW)	
	2025 (13 th)	2024 (12 th)
Assets		
Current assets	30,025,069,346	85,735,835,728
Cash and cash equivalents	4,417,207,942	40,764,729,065
Current trade receivables	13,965,899,808	10,187,211,402
Other current financial assets	903,528,708	5,493,571,667
Current financial assets at fair value through profit or loss	6,500,467,936	8,955,660,067
Current derivative financial assets	2,254,733,267	17,261,346,357
Other current assets	1,694,367,521	2,269,127,272
Current inventories	124,283,943	115,671,778
Current tax assets	164,580,221	688,518,120
Non-current assets	331,028,640,842	329,030,967,997
Non-current trade receivables	5,714,030,829	4,087,156,096
Investments in subsidiaries reported in separate financial statements	291,554,845,651	286,124,988,154
Property, plant and equipment	5,706,086,821	7,500,744,505
Right-of-use assets	14,429,153,822	16,800,429,288
Intangible assets and goodwill	8,787,576,231	1,737,261,785
Non-current financial assets at fair value through profit or loss	1,380,092,823	9,778,758,110
Other non-current financial assets	1,709,484,871	1,653,329,483
Other non-current assets	1,747,369,794	992,273,605
Non-current net defined benefit asset	0	356,026,971
Total assets	361,053,710,188	414,766,803,725
Liabilities		
Current liabilities	185,684,151,729	222,982,138,567
Current trade payables	6,183,388	0
Current loans received and current portion of non-current loans received	12,000,000,000	0
Other current financial liabilities	23,631,369,532	10,255,210,847
Current derivative financial liabilities	72,325,644,459	154,792,594,067
Current portion of convertible bonds	74,459,326,891	52,842,022,216
Current financial liabilities at fair value through profit or loss	0	1,845,458,333
Other current liabilities	3,261,627,459	3,244,433,098
Current tax liabilities	0	2,420,006
Non-current liabilities	18,637,784,073	16,773,855,188
Non-current net defined benefit liability	3,317,030,285	0
Long-term employee benefit liabilities	505,918,631	599,476,490
Non-current financial liabilities at fair value through profit or loss	0	0
Other non-current financial liabilities	13,746,290,563	15,609,920,548
Other non-current liabilities	500,216,678	12,250,158
Other non-current provisions	568,327,916	552,207,992
Total liabilities	204,321,935,802	239,755,993,755
Equity		
Issued capital	14,628,373,000	14,471,450,000
Capital surplus	549,031,241,883	526,645,689,887
Retained earnings (deficit)	-406,927,840,497	-366,106,329,917
Total equity	156,731,774,386	175,010,809,970
Total equity and liabilities	361,053,710,188	414,766,803,725

6. Separate Statements of Comprehensive Income

(Unit: KRW)

	2025 (13 th)	2024 (12 th)
Revenue	32,822,258,104	25,718,636,502
Operating expense	109,378,593,618	84,700,621,305
Operating income(loss)	-76,556,335,514	-58,981,984,803
Finance income	87,257,743,638	15,212,864,571
Finance costs	50,883,143,646	30,274,496,295
Other gains	40,489,225	97,404,309
Other losses	40,713,470	76,929,717
Profit (loss) before tax	-40,181,959,767	-74,023,141,935
Tax expense (income)	28,094,829	19,878,010
Profit (loss)	-40,210,054,596	-74,043,019,945
Other comprehensive income	-611,455,984	-467,946,575
Other comprehensive income that will not be reclassified to profit or loss, net of tax	-611,455,984	-467,946,575
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-611,455,984	-467,946,575
Comprehensive income	-40,821,510,580	-74,510,966,520
Earnings per share [abstract]		
Basic earnings (loss) per share	-1,380	-2,567
Diluted earnings (loss) per share	-2,604	-2,567

7. Separate Statements of Changes in Equity

(Unit: KRW)

	Separate	Issued capital	Elements of other stockholders equity	Retained earnings
2024 (12th)				
Statement of changes in equity				
Equity at beginning of period	238,273,562,974	14,351,138,500	515,517,787,871	-291,595,363,397
Increase (decrease) through transactions with owners, equity	11,248,213,516	120,311,500	11,127,902,016	0
Issue of equity	0	0	0	0
Increase (decrease) through exercise of warrants, equity	1,466,525,690	120,311,500	1,346,214,190	0
Bonus issue	0	0	0	0
Increase (decrease) through share-based payment transactions, equity	9,781,687,826	0	9,781,687,826	0
Comprehensive income	-74,510,966,520	0	0	-74,510,966,520
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-467,946,575	0	0	-467,946,575
Profit (loss)	-74,043,019,945	0	0	-74,043,019,945
Equity at end of period	175,010,809,970	14,471,450,000	526,645,689,887	-366,106,329,917
2025 (13th)				
Statement of changes in equity				
Equity at beginning of period	175,010,809,970	14,471,450,000	526,645,689,887	-366,106,329,917
Increase (decrease) through transactions with owners, equity	22,542,474,996	156,923,000	22,385,551,996	0
Issue of equity	0	0	0	0
Increase (decrease) through exercise of warrants, equity	3,263,863,780	156,923,000	3,106,940,780	0
Bonus issue	0	0	0	0
Increase (decrease) through share-based payment transactions, equity	19,278,611,216	0	19,278,611,216	0
Comprehensive income	-40,821,510,580	0	0	-40,821,510,580
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-611,455,984	0	0	-611,455,984
Profit (loss)	-40,210,054,596	0	0	-40,210,054,596
Equity at end of period	156,731,774,386	14,628,373,000	549,031,241,883	-406,927,840,497

8. Separate Statements of Cash Flows

(Unit: KRW)

	2025 (13 th)	2024 (12 th)
Cash flows from (used in) operating activities	-55,543,887,279	-52,467,740,199
Cash flows from (used in) operations	-52,961,554,766	-54,782,177,027
Interest received, classified as operating activities	668,192,481	4,347,566,619
Interest paid, classified as operating activities	-3,743,948,058	-1,620,033,157
Income taxes paid (refund), classified as operating activities	493,423,064	-413,096,634
Cash flows from (used in) investing activities	5,897,459,169	-105,350,404,385
Inflows of cash from investing activities	16,724,647,576	195,232,831,759
Proceeds from sales of short term Financial Instruments	5,000,000,000	190,000,000,000
Proceeds from sales of property, plant and equipment	53,163,086	54,103,257
Proceeds from sales of long-term financial instruments	0	50,000,000
Decrease in other guarantee deposit	95,441,812	0
Proceeds from sales of fair value financial asset	11,576,042,678	5,123,128,502
Proceeds from government grants	0	5,600,000
Decrease in loans	0	0
Decrease in guarantee deposits	0	0
Outflows of cash from investing activities	-10,827,188,407	-300,583,236,144
Purchase of property, plant and equipment	-286,517,404	-5,267,141,022
Purchase of intangible assets	-382,869,721	-298,300,000
Cash advances and loans made to other parties, classified as investing activities	-814,077,740	-648,396,392
Purchase of fair value financial asset	-8,423,417,142	-14,397,306,032
Purchase of investments in subsidiaries	-660,306,400	-274,793,790,380
Increase in other guarantee deposit	-60,000,000	-178,302,318
Purchase of short term Financial Instruments	-200,000,000	-5,000,000,000
Increase in guarantee deposits	0	0
Cash flows from (used in) financing activities	13,437,016,536	171,589,841,320
Inflows of cash from financing activities	27,263,863,780	172,966,525,690
Proceeds from exercise of share options	3,263,863,780	1,466,525,690
Proceeds from convertible bonds	0	171,500,000,000
Proceeds from short term borrowings	24,000,000,000	0
Issue of equity	0	0
Outflows of cash from financing activities	-13,826,847,244	-1,376,684,370
Payments of finance lease liabilities, classified as financing activities	-1,826,847,244	-1,376,684,370
Repayments of short term borrowings	-12,000,000,000	0
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-36,209,411,574	13,771,696,736
Cash and cash equivalents at beginning of period	40,764,729,065	26,627,399,641
Effect of exchange rate changes on cash and cash equivalents	-138,109,549	365,632,688
Cash and cash equivalents at end of period	4,417,207,942	40,764,729,065

Thank You

IR & Governance Team

Website

www.lunit.io

Email

ir@lunit.io

